Sherpa Healthcare Partners
夏尔巴投资
Sherpa Healthcare Partners (夏尔巴投资) is a China-based healthcare investor that elsewhere's corpus captures mainly through its syndicate appearances rather than any dedicated profile. Its pattern is consistent: it typically shows up as a follower or existing shareholder doubling down — co-investing in AusperBio's $63M Series B2 alongside Qiming in September 2025 , following Source Code Capital into Jianhai Technology's Series A3 and B rounds , and repeatedly adding to Sirius Pharma across its Series A, B, and B+ rounds through 2026 . It has also joined rounds in synthetic biology names like Bota Bio and Coteya Bio , usually alongside Source Code, Sequoia China, or 5Y Capital. Beyond these deal-flow mentions, elsewhere's corpus does not carry a fuller profile of the firm itself — its founding, fund size, or team aren't covered here.
AI-generated — may contain errors, please verify.
Coverage
Code Moment | Sirius Pharma Closes Nearly $40 Million Series B+ Round, Existing Shareholder Source Code Capital Continues to Double Down
Sirius Pharma announced the completion of a nearly $40 million Series B+ funding round, with existing shareholder Source Code Capital continuing to increase its stake.
MaHui Member Sirius Pharma Raises Over 300 Million Yuan in Series B, with Existing Investor Source Code Capital Increasing Stake
Solidifying an Innovative Footprint in RNA Therapeutics
AusperBio raises $63M in Series B2 funding co-led by Qiming Venture Partners
Haibo Pharmaceutical is a clinical-stage innovative drug company focused on the R&D of self-developed targeted small nucleic acid therapeutics, with "achieving clinical cure for chronic hepatitis B" as its core mission.
Code Moment | "Starna Therapeutics" Announces 150 Million Yuan Series A Funding Round, Source Code Capital Participates
Focus on extrahepatic delivery to build a core platform with global competitiveness.
Source Code Capital | "Coteya Bio" Announces Oversubscribed Series A Financing of Over 100 Million RMB, Led by Source Code Capital
Addressing a host of global challenges including environmental pollution, carbon emissions, and climate change
3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
As Fierce as August | 5Y News Monthly
The big news from last month.
5Y News | Synthetic Biology Company Bota Bio Raises Over $100 Million to Accelerate Efficient Design and Scaled Production of Bio-based Products
5Y Capital continues to pay close attention to emerging technologies at the intersection of information science and life sciences.
Synthetic biology company Bota Bio (Enhe Biotechnology) announced the completion of a Series B funding round exceeding $100 million, with existing shareholder Source Code Capital continuing to increase its stake.
Accelerating the design and production of high-performance, sustainable products through synthetic biology.
Source Code Capital portfolio company Jianhai Technology announced the completion of a 150 million yuan Series B investment, with existing shareholder Source Code Capital continuing to increase its stake.
Dedicated to advancing post-diagnosis disease management systems for patients, it has already partnered with more than 1,000 hospitals.
AI-powered disease management platform "Jianhai Technology" announces completion of RMB 60 million Series A3 funding round, led by Source Code Capital
It covers over 400 hospitals at or above the second-tier grade, and is exploring the use of AI for disease management and treatment.
618 Sales Roundup, World's Smartest Companies... 16 Updates and 7 Insights | FreeS Fund Blackboard · June
Do what's right, not what's easy.
